Trial Profile

A second phase III trial to investigate the efficacy of lasofoxifene for the treatment of vulvovaginal atrophy in postmenopausal women

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 27 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lasofoxifene (Primary)
Indications Atrophic vaginitis
Focus Therapeutic Use
Acronyms GARNET

Most Recent Events

29 Apr 2024 According to Sermonix Pharmaceuticals media release, results from two phase 3 Clinical trials (CTP 267412 and CTP 267394 ) will support ELAINE-3 study,which is currently recruiting pre- and post-menopausal subjects with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation
29 Apr 2024 According to Sermonix Pharmaceuticals media release, results from this study published in the Menopause: The Journal of The Menopause Society.
29 Apr 2024 Results published in the Sermonix Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com